Radiotheranostics is a field of rapid growth with some approved treatments including ^(131)I for thyroid cancer, ^(223)Ra for osseous metastases, ^(177)Lu-Dotatate for neuroendocrine tumors, and ^(177)Lu-PSMA for prostate cancer, and several more under investigation. In this review, we will cover the fundamentals of radiotheranostics, the key clinical studies that have led to current success, future developments with new targets, radionuclides and platforms, challenges with logistics and…
Ann Oncol. 2023 Mar 14:S0923-7534(23)00113-8. doi: 10.1016/j.annonc.2023.03.001. Online ahead of print.
ABSTRACT
Radiotheranostics is a field of rapid growth with some approved treatments including 131I for thyroid cancer, 223Ra for osseous metastases, 177Lu-Dotatate for neuroendocrine tumors, and 177Lu-PSMA for prostate cancer, and several more under investigation. In this review, we will cover the fundamentals of radiotheranostics, the key clinical studies that have led to current success, future developments with new targets, radionuclides and platforms, challenges with logistics and reimbursement and, lastly, forthcoming considerations regarding dosimetry, identifying the right line of therapy, artificial intelligence and more.
PMID:36924989 | DOI:10.1016/j.annonc.2023.03.001
English
Arabic
Russian
French
Chinese (Simplified)
Japanese
Portuguese
Spanish